ANGPTL2-mediated epigenetic repression of MHC-I in tumor cells accelerates tumor immune evasion

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Major histocompatibility complex class I (MHC-I) downregulation aids tumor immune evasion.
• Angiopoietin-like protein 2 (ANGPTL2) was previously shown to promote tumor progression in a Xp11.2 translocation renal cell carcinoma (tRCC) mouse model.
• The precise molecular mechanisms of ANGPTL2's role in tRCC remained unclear.

Purpose of the Study:

• To elucidate the molecular mechanisms by which ANGPTL2 promotes tumor progression and immune evasion in tRCC.
• To investigate the impact of ANGPTL2 deficiency on tumor growth and anti-tumor immunity in a tRCC mouse model.
• To identify ANGPTL2-mediated pathways affecting MHC-I expression and T-cell recognition.

Main Methods:

• Utilized a tRCC mouse model with targeted deficiency of ANGPTL2 in renal tubular epithelial cells.
• Assessed tumor progression, CD8+ T-cell infiltration, and MHC-I expression in tumor tissues.
• Investigated the ANGPTL2-α5β1 integrin pathway and its effect on Polycomb Repressive Complex 2 (PRC2)-mediated MHC-I repression.

Main Results:

• ANGPTL2 deficiency slowed tumor progression and increased activated CD8+ T-cell infiltration in the tRCC mouse model.
• Angptl2-deficient tumor cells exhibited enhanced interferon-γ-induced MHC-I expression.
• The ANGPTL2-α5β1 integrin pathway was found to promote PRC2-mediated repression of MHC-I expression in tumor cells, increasing susceptibility to CD8+ T-cell-mediated killing.

Conclusions:

• ANGPTL2 signaling in tumor cells contributes to immune evasion by suppressing MHC-I expression.
• Targeting the ANGPTL2 pathway in tumor cells represents a potential therapeutic strategy to enhance T-cell-mediated anti-tumor immunity.
• Restoring MHC-I expression through ANGPTL2 inhibition could improve the efficacy of cancer immunotherapy.